Amy Park, MD
Urogynecology and Reconstructive Pelvic Surgery · Cleveland, OHNPI 1053328625
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (50.3%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. AbbVie accounts for 75.7% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2019 at $5,746 and has fallen 94.6% since, to $311 in 2025.
Across 66 payments — averaging $171.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$9K
- Boston Scientific$1K
- Coloplast$830
- Axonics, Inc.$484
- AMAG Pharmaceuticals, Inc.$107
- Medtronic$107
- plus $132 from 2 others
What the payments were for
- Consulting fees$1,37512%
- Speaking & faculty fees$5,70050%
- Travel & lodging$8377%
- Food & beverage$3,18328%
- Education$2392%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 35 | $8,582 |
| Boston Scientific | 11 | $1,093 |
| Coloplast | 8 | $830 |
| Axonics, Inc. | 5 | $484 |
| AMAG Pharmaceuticals, Inc. | 2 | $107 |
| Medtronic | 2 | $107 |
| Myovant Sciences Inc. | 2 | $95 |
| Applied Medical Resources Corporation | 1 | $37 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BOTOX$8,082
- ALTIS$520
- Axonics$484
- Solyx SIS System$377
- Advantage System$304
- Orilissa$124
- Bulkamid$111
How this compares
$11,335 in reported general payments places this provider in the 80th percentile of 60 urogynecology and reconstructive pelvic surgery providers in Ohio.
See all urogynecology and reconstructive pelvic surgery providers in Ohio →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 20 | $21,914 |
| Estradiol | 105 | $9,445 |
| Trospium Chloride | 45 | $4,237 |
| Trimethoprim | 21 | $993 |
| NitrofurantoinNitrofurantoin Macrocrystal | 16 | $719 |
| Clobetasol Propionate | 16 | $517 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 35 | $298 |
| Oxybutynin Chloride ErOxybutynin Chloride | 14 | $207 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 78 | $88 |
Paid to pharmacies, not to this prescriber.
Other urogynecology and reconstructive pelvic surgery in Cleveland
- Emily SlopnickCleveland$37K
- Ly Hoang RobertsCleveland$23K
- Marie ParaisoCleveland$20K
- Omer AnisCleveland$17K
- Chen ShenharCleveland$13K
- Katie PropstCleveland$6K
- Anne SammarcoCleveland$5K
- Amy GeeCleveland$5K
- Shannon WallaceCleveland$5K
- Graham ChapmanCleveland$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.